10-K: Dynatronics Faces Going Concern Doubt Amid Deepening Losses

Dynatronics Corporation reported a substantial net loss and significant impairment charges for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net sales for fiscal year 2025 decreased by 15.8% to $27.39 million, down from $32.53 million in fiscal year 2024, primarily due to reduced OEM customer volume and lower demand for orthopedic soft bracing products.
• Gross profit declined by 21.3% to $6.01 million (21.9% of net sales) in fiscal year 2025, compared to $7.63 million (23.5% of net sales) in the prior year.
• The company incurred significant non-cash impairment charges totaling $950,293 for intangible assets and $7,116,614 for goodwill in fiscal year 2025.
• Net loss widened significantly to $10.90 million in fiscal year 2025, from a net loss of $2.70 million in fiscal year 2024.
• Net loss attributable to common stockholders was $11.60 million ($1.43 per share) for fiscal year 2025, compared to $3.43 million ($1.00 per share) for fiscal year 2024.
• Cash and cash equivalents decreased to $326,344 as of June 30, 2025, from $483,918 as of June 30, 2024.
• Working capital decreased substantially to $718,000 as of June 30, 2025, from $2.85 million as of June 30, 2024.
• The company received a notice of default and reservation of rights from its lender, Gibraltar Business Capital, LLC, on September 16, 2025, for failing to comply with its fixed charge coverage ratio covenant.

Sentiment

Score: 1

Explanation: The company is in a precarious financial position, marked by significant revenue decline, widening losses, substantial impairment charges, deteriorating liquidity, and a formal notice of default from its lender, raising substantial doubt about its ability to continue as a going concern. This indicates extremely negative sentiment.

Positives

• Selling, General, and Administrative (SG&A) expenses decreased by $1.44 million, or 14.6%, in fiscal year 2025, driven by reductions in salaries, benefits, and professional expenses.
• Interest expense, net, decreased slightly by 1.9% to $409,906, primarily due to a lower average outstanding balance on the line of credit.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses, negative cash flows, and reduced liquidity.
• Net sales decreased by 15.8% year-over-year, indicating a significant decline in demand and OEM customer volume.
• Gross profit margin deteriorated from 23.5% to 21.9% of net sales.
• The company recorded substantial non-cash impairment charges of $950,293 for intangible assets and $7,116,614 for goodwill in fiscal year 2025.
• Net loss widened significantly to $10.90 million in fiscal year 2025, compared to $2.70 million in the prior year.
• Net loss per common share increased to $1.43 from $1.00, reflecting deeper losses and dilution from preferred stock dividends.
• Working capital decreased by over 70% year-over-year, severely impacting liquidity.
• The current ratio declined from 1.4 to 1 to 1.1 to 1, indicating a weaker short-term financial position.
• The company received a notice of default from its lender for non-compliance with a financial covenant, which could lead to acceleration of debt.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring operating losses, negative cash flows, and reduced liquidity.
• Dependence on third-party manufacturers for electrotherapy products, with risks of quality issues, delays, cost overruns, and supply interruptions.
• Disruption of the supply chain due to weather, natural disasters, pandemics, strikes, government action, or disputes with suppliers.
• Inflation and price fluctuations of raw materials, energy, and labor could adversely affect profitability.
• Economic uncertainty and geopolitical instability (e.g., conflicts in Ukraine and the Middle East, Red Sea attacks) could materially impact business.
• Risks related to health epidemics and other widespread outbreaks of contagious disease disrupting manufacturing and supply chain.
• History of losses and uncertainty about achieving future profitability.
• Potential for future non-cash impairment charges if stock price declines, cash flows are adverse, or key assumptions change.
• Need for additional funding and potential inability to raise capital on favorable terms or at all.
• Challenges in managing growth through acquisitions, including integration difficulties, loss of employees, unbudgeted costs, and failure to achieve synergies.
• Failure to establish new sales and distribution relationships or maintain existing ones, or ineffective third-party distributors.
• Significant effects of healthcare reform in the United States on business and growth.
• Extensive regulation by numerous government agencies (FDA, FTC, foreign authorities) and potential non-compliance penalties.
• Changing market patterns, including a shift towards evidence-based practices, could shrink demand for products lacking sufficient efficacy evidence.
• Consolidation trends among customers and increased pricing pressures from group purchasing organizations (GPOs).
• Increased scrutiny by government agencies on sales, marketing, pricing, and relationships with healthcare providers, with risks of large civil and criminal penalties.
• Special risks associated with international commercial activities, including heightened corruption and trade sanctions risks (FCPA, U.K. Anti-Bribery Act).
• Significant tariffs or other restrictions on imports or counter-measures by foreign countries could harm revenue and results of operations.
• Failure to obtain regulatory approval in foreign jurisdictions could limit market access.
• Complex and evolving laws and regulations regarding privacy and data protection (CCPA, GDPR, CSL) could increase compliance costs and limit product adoption.
• Market access limitations due to the emergence of GPOs and difficulty in securing significant GPO contracts.
• Approximately 40% of the workforce is subject to a collective bargaining agreement, with risks of negotiation failure, increased labor costs, or work stoppages.
• Inadequate protection of proprietary intellectual property (patents, trade secrets) and potential intellectual property litigation.
• Market and technological obsolescence of the company's approximately 2,500 products.
• Inability to effectively develop and market products against competitors in a highly competitive industry.
• Dependence on a limited number of third-party suppliers for components and raw materials, with risks of supply disruptions and increased costs.
• Adverse effects from product liability claims, unfavorable court decisions, or legal settlements.
• Covenants in the loan documents (e.g., fixed charge coverage ratio) may restrict business operations, and non-compliance could lead to debt acceleration.
• Competition from large, well-established medical device companies with significant resources.
• Dependence on senior management, sales and marketing team, engineering team, and other qualified personnel, with risks from loss of key individuals.
• Failures in, material damage to, or interruptions in information technology systems, software, or websites, including cyber-attacks.
• A decline in the price of common stock could affect the ability to raise working capital.
• Stock price volatility due to various factors, including operating results, market expectations, and economic conditions.
• Substantial dilution for existing shareholders from conversion of preferred stock, exercise of options/warrants, and future stock issuances.
• Ability to issue preferred stock with greater rights and preferences could delay or prevent takeover attempts.
• Trading on the OTCQB Venture Market could lead to reduced liquidity, delayed transactions, and potential 'penny stock' rules application.
• Potential strategies to deregister common stock under the Exchange Act ('going dark') could negatively affect liquidity and trading prices and result in less disclosure.

Future Outlook

Management is focused on driving profitability through business optimization, new product launches, and building its restorative products platform. For fiscal year 2026, the company plans to enhance strategic partnerships, increase operating profitability through disciplined product portfolio management, and pursue merger and acquisition opportunities in its core markets. It also intends to transition production of therapeutic modalities to internal operations to reduce costs, enhance quality, and improve supply chain reliability, while also reducing excess inventory through discounted sales.

Management Comments

• We are confident that the steps we have taken will position the Company for success moving forward.
• We are actively pursuing an acquisition strategy to consolidate other manufacturers in our core markets (i.e. physical therapy, rehabilitation, orthopedics, pain management, and athletic training).
• The Company is in the process of creating a comprehensive plan to address these challenges to improve performance, including cost reduction initiatives, streamlining operational processes, pursuing new revenue streams through product diversification, and transitioning production of the majority of our therapeutic modalities from a contract manufacturer to internal operations.
• This shift to in-house production aims to reduce costs by eliminating third-party markups, enhance quality control with direct oversight of manufacturing processes, and improve supply chain reliability to mitigate risks of disruptions.
• The Company is also evaluating the current inventory position and working to reduce the amount of excess inventory exposure by promoting discounted prices to convert the excess inventory to cash.

Industry Context

The medical device industry is highly competitive and fragmented, with numerous competitors of varying sizes. The industry is subject to rapid technological change and increasing scrutiny from regulatory bodies. There is a trend towards evidence-based practices and consolidation among healthcare providers and group purchasing organizations (GPOs), leading to greater pricing pressures. Dynatronics operates within this environment, facing challenges from larger, more established competitors and difficulties in securing significant GPO contracts. The company's strategy to pursue M&A opportunities suggests an attempt to consolidate within its niche, while its shift to in-house manufacturing aims to counter supply chain and cost pressures prevalent in the broader manufacturing sector.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or global benchmarks to assess results against industry standards. However, it notes that the company competes against larger and more established medical device companies like Enovis and Ossur, which generally possess greater resources for R&D, marketing, and distribution.
• The company's gross profit margin of 21.9% in FY2025 is lower than typical for established medical device companies, which often range from 40-70% depending on product complexity and market position, indicating significant cost pressures or lower-margin product mix.
• The substantial goodwill and intangible asset impairment charges suggest that the company's acquired assets are not performing as expected, a common issue in M&A but significant in magnitude for Dynatronics.
• The recurring operating losses and 'going concern' doubt are significantly below industry standards for healthy, publicly traded companies in the medical device sector, which are typically expected to be profitable and cash-flow positive.

Corporate Governance

Legal Proceedings

• No pending legal proceedings of a material nature to which the company is a party or to which any of its property is the subject.

Related Party Transactions

• Lease of Northvale, New Jersey manufacturing and office facility from employees, shareholders, and entities controlled by shareholders (previous principals of businesses acquired by the Company). Combined expenses for these related-party transactions totaled $1,222,948 for FY2025 and $1,339,252 for FY2024.
• The Minnesota facility operating lease was previously associated with related parties but as of April 2025, it is no longer associated with related parties.

Stakeholder Impact

• Shareholders face significant dilution from preferred stock dividends paid in common stock and potential future equity raises, as well as substantial risk to investment value due to the 'going concern' doubt and stock price volatility.
• Employees, particularly the 40% covered by a collective bargaining agreement, could be impacted by potential labor disputes or cost reduction initiatives.
• Customers may experience impacts from supply chain disruptions, product obsolescence, or changes in product offerings due to strategic shifts.
• Creditors, specifically Gibraltar Business Capital, LLC, are directly impacted by the company's default on loan covenants, potentially leading to debt acceleration and enforcement of security interests.
• Suppliers may face renegotiated terms or reduced orders as the company focuses on cost reduction and in-house manufacturing.

Next Steps

• Implement cost reduction initiatives and streamline operational processes.
• Pursue new revenue streams through product diversification.
• Transition production of therapeutic modalities from contract manufacturers to internal operations.
• Reduce excess inventory by promoting discounted prices.
• Continue efforts to improve sales and operating efficiency.
• Evaluate and take action to preserve adequate liquidity.
• Actively pursue merger and acquisition opportunities in core markets.
• Address the default notice from Gibraltar Business Capital, LLC and comply with loan covenants.

Key Dates

Recommendation

The company's financial health is severely distressed, evidenced by a substantial net loss of $10.9 million, significant impairment charges exceeding $8 million, a 15.8% decline in net sales, and a drastic reduction in working capital. The explicit 'substantial doubt about its ability to continue as a going concern' from both management and the independent auditor, coupled with a formal notice of default from its primary lender, indicates an extremely high level of financial risk. While management outlines plans for improvement, their success is not guaranteed, and the immediate outlook is highly negative. Investors face significant risk of further capital loss and dilution.

Keywords

Medical Devices, Physical Therapy, Rehabilitation, Orthopedics, Pain Management, Athletic Training, SEC Filing, 10-K, Financial Results, Going Concern, Impairment Charges, Net Loss, Working Capital, Supply Chain, Regulatory Compliance, Healthcare Industry, Corporate Governance, Stock Volatility, Preferred Stock, Debt Default